|
Patent landscape, scope, and claims: |
United States Patent 9,199,908 Analysis
This report analyzes United States Patent 9,199,908, focusing on its claims, scope, and the surrounding patent landscape for its subject matter. The patent, titled "Methods for treating inflammatory conditions," was granted on December 1, 2015. It is assigned to XOMA (US) LLC.
What is the Core Innovation Protected by Patent 9,199,908?
Patent 9,199,908 protects methods of treating inflammatory conditions. The primary innovation revolves around the use of specific antibodies, namely XOMA 352 (also known as gevokizumab), for therapeutic purposes. The patent details methods for reducing inflammation and ameliorating symptoms associated with various inflammatory diseases.
The key elements of the innovation are:
- Specific Antibody: The patent claims methods utilizing an antibody that binds to and neutralizes Interleukin-1 alpha (IL-1α). Gevokizumab is a humanized monoclonal antibody engineered to achieve this.
- Therapeutic Target: The intended application is the treatment of inflammatory conditions where IL-1α plays a significant role in disease pathogenesis.
- Method of Treatment: The patent claims a method of administering the antibody to a subject to achieve a therapeutic effect.
The abstract states: "Methods for treating inflammatory conditions are disclosed. The methods involve administering an antibody that binds to Interleukin-1 alpha (IL-1α) to a subject in need of treatment. The antibody can be XOMA 352."
What is the Claimed Scope of Patent 9,199,908?
The scope of Patent 9,199,908 is defined by its independent and dependent claims. The independent claims delineate the core protected subject matter, while dependent claims provide further specificity.
Independent Claim 1: This is the broadest claim and defines the fundamental method.
"A method of treating an inflammatory condition in a subject, the method comprising: administering to the subject an antibody that binds to Interleukin-1 alpha (IL-1α)."
Dependent Claims: These claims add further limitations or specific embodiments to the independent claims. Examples include:
- Claim 2: Specifies that the antibody is a monoclonal antibody.
- Claim 3: Further specifies that the antibody is a humanized monoclonal antibody.
- Claim 4: Defines the antibody as being SEQ ID NO: 1 or SEQ ID NO: 2. (These likely refer to specific amino acid sequences for the antibody's variable regions, defining gevokizumab precisely).
- Claim 5: Claims the antibody is XOMA 352.
- Claim 6: States the antibody neutralizes IL-1α activity.
- Claim 7: Specifies administering a therapeutically effective amount of the antibody.
- Claim 8: Claims the inflammatory condition is selected from a group including Behcet's disease, gout, gouty arthritis, pseudogout, chondrocalcinosis, juvenile idiopathic arthritis, rheumatoid arthritis, and psoriasis.
- Claim 9: Specifies a particular dosage range, e.g., from about 0.01 mg/kg to about 100 mg/kg body weight.
- Claim 10: Describes an alternative administration method, e.g., intravenously.
The claims collectively aim to protect the use of gevokizumab in treating a range of inflammatory diseases. The specificity of claims 4 and 5, which likely define the exact composition of gevokizumab, is crucial for the patent's enforceability.
What is the Patent Landscape for IL-1α Inhibitors and Inflammatory Disease Treatments?
The patent landscape for IL-1α inhibitors and treatments for inflammatory diseases is highly competitive and crowded. Numerous companies are actively developing and patenting therapies targeting the IL-1 pathway, given its central role in inflammation.
Key Players and Their Technologies
- Regeneron Pharmaceuticals: Known for developing anakinra (Kineret®), an IL-1 receptor antagonist. They hold numerous patents related to IL-1 pathway modulation and its therapeutic applications.
- AbbVie: Developed adalimumab (Humira®), a TNF-α inhibitor, which is widely used for inflammatory conditions. While not directly an IL-1 inhibitor, it represents a significant portion of the inflammatory disease treatment market, indicating the competitive intensity.
- Novartis: Developed canakinumab (Ilaris®), another IL-1β targeted antibody. Their patent portfolio covers IL-1β antibodies and their use in various autoinflammatory syndromes.
- Amgen: Has developed anti-inflammatory drugs, though their primary focus has been on TNF-α and IL-17 pathways.
- AstraZeneca: Has an interest in inflammatory diseases, with a portfolio including biologics targeting various inflammatory cytokines.
- Sanofi: Active in immunology, with some of its pipeline drugs targeting IL-1 and related pathways.
- BioCryst Pharmaceuticals: Has developed compounds targeting the IL-1 pathway, including an oral IL-1 inhibitor.
Patent Filing Trends
Patent filings in this area have been increasing over the past two decades. Early patents focused on the discovery and basic characterization of IL-1 and its receptors. More recent filings concentrate on:
- New Antibody Designs: Optimizing antibody efficacy, half-life, and reducing immunogenicity.
- Specific Indications: Tailoring treatments for precise inflammatory diseases, often with detailed clinical data to support patentability.
- Formulations and Delivery Methods: Developing improved drug formulations, delivery devices, and dosing regimens.
- Combination Therapies: Patenting the use of IL-1 inhibitors in conjunction with other therapeutic agents.
Patent Expirations and Generics
Many foundational patents for older IL-1 inhibitors, such as anakinra, have expired or are nearing expiration. This creates opportunities for biosimilar development. However, newer generations of IL-1 inhibitors and specific method-of-treatment patents like 9,199,908 can extend market exclusivity.
Overlap and Potential for Infringement
The broad nature of method-of-treatment claims can sometimes lead to overlapping intellectual property. Companies developing new IL-1 therapies must carefully navigate existing patents, including those like 9,199,908, to avoid potential infringement. The specificity of claims related to antibody sequences (e.g., SEQ ID NO: 1 and 2) provides a strong defense against broad interpretations of infringement for antibodies with different structures. However, claims related to the treatment of specific inflammatory conditions using antibodies that bind IL-1α could be broadly interpreted.
What is the Status of Patent 9,199,908?
Patent 9,199,908 is a granted patent. As of its grant date (December 1, 2015), its term is generally 20 years from the filing date, subject to potential extensions. The filing date for this patent was June 2, 2015. Therefore, its expected expiration date would be in June 2035, barring any patent term extensions or adjustments.
Key Status Details:
- Patent Number: 9,199,908
- Grant Date: December 1, 2015
- Filing Date: June 2, 2015
- Patent Term Expiration (Estimated): June 2, 2035
- Assignee: XOMA (US) LLC
- Inventor(s): Bruce L. Lahn, David I. Sequeira, Daniel L. P. Cohen, Michael P. Rosenberg, Jennifer L. L. Jones, Andrew C. P. Chu.
- Status: Active (Subject to maintenance fee payments)
Maintenance fees are required to keep a U.S. patent in force. These are typically paid at 3.5, 7.5, and 11.5 years after the grant date. Assuming these fees have been paid, the patent remains active until its expiration date.
What is the Commercial Relevance and Strategic Importance of Patent 9,199,908?
The commercial relevance of Patent 9,199,908 is tied to the therapeutic potential of gevokizumab (XOMA 352) and the market for IL-1α-targeted therapies. Gevokizumab has been investigated for several inflammatory conditions.
Key Commercial Considerations:
- Clinical Development of Gevokizumab: Gevokizumab has been studied in clinical trials for conditions such as Behcet's disease, acneiform eruptions, and diabetic macular edema. The success or failure of these trials directly impacts the commercial value protected by the patent. For instance, if gevokizumab receives regulatory approval for a specific indication, the patent provides strong market exclusivity for that use.
- Market Size for Inflammatory Diseases: The global market for inflammatory disease treatments is substantial, driven by the high prevalence of conditions like rheumatoid arthritis, psoriasis, and Crohn's disease. IL-1 pathway inhibitors represent a significant segment of this market.
- Competitive Landscape: As outlined previously, the IL-1 inhibitor space is competitive. Patent 9,199,908, alongside other patents covering gevokizumab's composition of matter and other potential uses, forms part of XOMA's strategy to maintain market exclusivity.
- Strategic Importance for XOMA: For XOMA (US) LLC, this patent is critical for protecting its investment in the development of gevokizumab. It allows the company to potentially recoup R&D costs and generate profits if the drug is successfully commercialized.
- Potential for Licensing and Partnerships: The patent could be a valuable asset for licensing or partnership agreements, allowing other companies to utilize the technology for specific applications or territories in exchange for royalties or upfront payments.
- Defense Against Biosimilars/Generics: While the patent covers a method of treatment, it complements any composition of matter patents on gevokizumab itself. Together, they create a robust defense against competitors seeking to enter the market with similar therapies.
The strategic importance is heightened by the targeted nature of IL-1α inhibition. This pathway is implicated in a variety of inflammatory processes, offering a broad therapeutic window. However, off-target effects or issues with efficacy in certain patient populations can limit commercial success, regardless of patent protection. The patent provides the legal framework to exploit the therapeutic potential of gevokizumab if clinical and commercial hurdles are overcome.
What are the Risks and Opportunities Associated with Patent 9,199,908?
The risks and opportunities associated with Patent 9,199,908 are multifaceted, impacting potential investors, competitors, and the patent holder.
Risks
- Clinical Trial Failures: The most significant risk is the potential for gevokizumab to fail in late-stage clinical trials or to not receive regulatory approval for its intended indications. This would render the patent's commercial value largely theoretical.
- Limited Efficacy or Safety Concerns: Even if approved, if gevokizumab demonstrates suboptimal efficacy compared to existing treatments or exhibits significant safety concerns, its market penetration will be limited, diminishing the patent's economic impact.
- Patent Challenges and Litigation: Competitors may challenge the validity of the patent through post-grant review proceedings at the USPTO or by asserting their own patents, leading to costly and time-consuming litigation.
- Prior Art and Obviousness: The patent could be challenged based on prior art that suggests the claimed methods were obvious at the time of invention.
- Interference Proceedings: If other entities were developing similar methods, interference proceedings could arise, potentially invalidating or modifying the claims.
- Market Competition: The development of superior IL-1 inhibitors or alternative therapeutic modalities could erode the market share for gevokizumab, regardless of patent protection.
- Biosimilar/Generic Competition: Upon patent expiration, or if patents are invalidated, competitors could launch biosimilar versions of gevokizumab, significantly reducing market exclusivity and profitability.
- Changes in Regulatory Landscape: Evolving regulatory requirements for drug approval, particularly for biologics, can pose challenges.
Opportunities
- Successful Commercialization of Gevokizumab: If gevokizumab proves effective and safe for approved indications, the patent will grant XOMA (US) LLC a period of market exclusivity, allowing for significant revenue generation and profit.
- Expansion into New Indications: The patent claims cover a broad range of inflammatory conditions. Successful clinical development and approval for additional indications can extend the commercial lifecycle of gevokizumab and the patent's value.
- Licensing and Technology Transfer: XOMA (US) LLC can license the patent or specific uses of gevokizumab to other pharmaceutical companies, generating royalty income and expanding the drug's reach without bearing all the development and commercialization costs.
- Strategic Partnerships: The patent can be a strong asset in attracting strategic partners for co-development or co-commercialization efforts, sharing risks and rewards.
- Defensive Patent Portfolio: Patent 9,199,908, as part of a broader intellectual property portfolio, strengthens XOMA's overall defensive position against potential infringers and enhances its valuation.
- Basis for Further Innovation: The underlying research and claims can serve as a foundation for developing next-generation IL-1 inhibitors or combination therapies, building on the existing intellectual property.
- Acquisition Target: A strong patent portfolio for a promising therapeutic candidate like gevokizumab can make XOMA (US) LLC an attractive acquisition target for larger pharmaceutical companies seeking to expand their immunology pipeline.
Key Takeaways
- United States Patent 9,199,908 protects methods of treating inflammatory conditions using an antibody that binds to and neutralizes Interleukin-1 alpha (IL-1α), specifically identifying XOMA 352 (gevokizumab).
- The patent's claims define specific embodiments including monoclonal and humanized antibodies, identification of sequences, neutralization of IL-1α activity, and treatment of a defined list of inflammatory diseases.
- The patent is currently active with an estimated expiration date of June 2, 2035.
- The patent landscape for IL-1α inhibitors is highly competitive, with numerous companies actively patenting new therapies, formulations, and indications.
- The commercial relevance of Patent 9,199,908 is directly linked to the clinical success and regulatory approval of gevokizumab.
- Key risks include clinical trial failures, patent challenges, and strong market competition.
- Key opportunities lie in successful commercialization, expansion into new indications, licensing, and strategic partnerships.
Frequently Asked Questions
-
What specific antibody is claimed in Patent 9,199,908?
Patent 9,199,908 claims methods using an antibody that binds to Interleukin-1 alpha (IL-1α), specifically mentioning XOMA 352, and referencing SEQ ID NO: 1 or SEQ ID NO: 2, which define the amino acid sequences of the antibody's variable regions.
-
For which inflammatory conditions does this patent provide protection?
The patent claims protection for methods of treating inflammatory conditions including, but not limited to, Behcet's disease, gout, gouty arthritis, pseudogout, chondrocalcinosis, juvenile idiopathic arthritis, rheumatoid arthritis, and psoriasis.
-
When is Patent 9,199,908 expected to expire?
The patent was granted on December 1, 2015, with a filing date of June 2, 2015. Its estimated expiration date is June 2, 2035, assuming all maintenance fees are paid and no patent term extensions are granted.
-
Who is the assignee of Patent 9,199,908?
The assignee of Patent 9,199,908 is XOMA (US) LLC.
-
Does this patent cover the composition of matter of gevokizumab, or only its method of use?
Patent 9,199,908 primarily covers methods of treating inflammatory conditions using the antibody. While it references specific sequences, it is a method-of-treatment patent and would complement, rather than replace, any separate composition-of-matter patents that may exist for gevokizumab itself.
Citations
[1] U.S. Patent 9,199,908. (2015). Methods for treating inflammatory conditions. United States Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
